-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Tcr2 Therapeutics Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2018 to Q1 2023.
- Tcr2 Therapeutics Inc. Operating Income (Loss) for the quarter ending March 31, 2023 was -$41.5M, a 42.1% decline year-over-year.
- Tcr2 Therapeutics Inc. Operating Income (Loss) for the twelve months ending March 31, 2023 was -$166M, a 54.4% decline year-over-year.
- Tcr2 Therapeutics Inc. annual Operating Income (Loss) for 2022 was -$153M, a 53.9% decline from 2021.
- Tcr2 Therapeutics Inc. annual Operating Income (Loss) for 2021 was -$99.7M, a 45.2% decline from 2020.
- Tcr2 Therapeutics Inc. annual Operating Income (Loss) for 2020 was -$68.7M, a 33.7% decline from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)